MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
24h
Current
Min
344.24
Max
354.44
Income | 93M 94M |
---|---|
Sales | 198M 1.3B |
Profit margin | 7.171 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +7.08% upside |
Next Earnings | 10 lis 2025 |
---|
Market Cap | 22B |
---|---|
Previous open | 341.04 |
Previous close | 344.24 |
By Acuity
50%
50%
149 / 371 Ranking in Healthcare
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
12 maj 2025, 02:16 UTC
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs
DJ
Read
29 sty 2025, 15:59 UTC
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
DJ
Read
27 lis 2024, 15:22 UTC
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment
DJ
Read
21 lis 2024, 14:45 UTC
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
DJ
Read
22 paź 2024, 18:39 UTC
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
DJ
Read
6 sie 2025, 10:01 UTC
BeOne Medicines Narrows FY25 View To Rev $5.0B-$5.3B >ONC
DJ
Read
6 sie 2025, 10:01 UTC
BeOne Medicines 2Q Rev $1.3B >ONC
DJ
Read
6 sie 2025, 10:01 UTC
BeOne Medicines 2Q Adj EPS $2.25 >ONC
DJ
Read
6 sie 2025, 10:00 UTC
BeOne Medicines 2Q EPS 84c >ONC
DJ
Read
9 lip 2025, 09:17 UTC
Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ
DJ
Read
7 maj 2025, 10:07 UTC
BeiGene Maintains 2025 Expense Guidance of $4.1B to $4.4B >ONC
DJ
Read
7 maj 2025, 10:06 UTC
BeiGene Backs 2025 Rev $4.9B-$5.3B >ONC
DJ
Read
7 maj 2025, 10:05 UTC
BeiGene 1Q Net $1.27M >ONC
DJ
Read
7 maj 2025, 10:04 UTC
BeiGene Says to Rename Company to BeOne Medicines >ONC
DJ
Read
7 maj 2025, 10:02 UTC
BeiGene 1Q EPS $0.00 >ONC
DJ
Read
7 maj 2025, 10:02 UTC
BeiGene 1Q Rev Increased 49% >ONC
DJ
Read
7 maj 2025, 10:00 UTC
BeiGene 1Q Rev $1.12B >ONC
DJ
Read
27 lut 2025, 11:07 UTC
BeiGene Sees 2025 Rev $4.9B-$5.3B >ONC
DJ
Read
27 lut 2025, 11:06 UTC
BeiGene 4Q Global BRUKINSA Rev of $828M >ONC
DJ
Read
27 lut 2025, 11:06 UTC
BeiGene 4Q Loss/Shr 11c >ONC
DJ
Read
27 lut 2025, 11:06 UTC
BeiGene 4Q Rev $1.13B >ONC
DJ
Read
12 lis 2024, 11:01 UTC
BeiGene 3Q Loss/Shr 9c >BGNE
DJ
Read
12 lis 2024, 11:01 UTC
BeiGene 3Q Rev $1B >BGNE
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 358.88 USD 7.08%
High 399 USD
Low 322 USD
Based on 13 Wall Street analysts offering 12 month price targets forBeOne Medicines Ltd ADR - Dist in the last 3 months.
By TipRanks
Strong Buy
13 ratings
12
Buy
1
Hold
0
Sell
Based on 13 analysts giving stock ratings to BeOne Medicines Ltd ADR - Dist in the past 3 months.
By Acuity
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Operating profit
$